---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-002983"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:16:45.809742+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial

## Summary
- FDA agreed existing data can directly support Phase 2 breast cancer trial design.
- Plan to initiate Phase 2 study in advanced/metastatic breast cancer in Q3 2024.
- Breast cancer represents larger market than colorectal; potential for >250,000 patients/year.
- Company identified breast cancer KOLs for scientific advisory board.

## SEC filing metadata
- accession: 0001493152-24-002983
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/0001493152-24-002983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-002983
- JSON: https://secwatch.observer/filing/0001493152-24-002983.json
- Plain text: https://secwatch.observer/filing/0001493152-24-002983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.